Monocytes with Oncogenic Mutation  JAK2 V617F  as a Tool for Studies of the Pathogenic Mechanisms of Myelofibrosis

A. A. Silyutina; I. I. Gin; S. S. Prikhod’ko; S. V. Zhuk; P. A. Butylin; A. Yu. Zaritskii

doi:10.1007/s10517-018-4033-x

Monocytes with Oncogenic Mutation JAK2 V617F as a Tool for Studies of the Pathogenic Mechanisms of Myelofibrosis

Авторы: Silyutina A.¹, Gin I.¹, Prikhod’ko S.¹, Zhuk S.¹, Butylin P.¹, Zaritskii A.¹
Учреждения:
1. Research Laboratory of Oncohematology, Institute of Hematology, V. A. Almazov National Medical Research Centre
Выпуск: Том 164, № 4 (2018)
Страницы: 569-575
Раздел: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
URL: https://journals.rcsi.science/0007-4888/article/view/239750
DOI: https://doi.org/10.1007/s10517-018-4033-x
ID: 239750

Цитировать

Полный текст

Открытый доступ
Доступ закрыт

Доступ предоставлен
Доступ закрыт

Только для подписчиков

Аннотация
Об авторах
Список литературы
Статистика

Аннотация

We analyzed previously generated stable monocyte-derived cell line carrying mutation JAK2 V617F. Evaluation of the expression of pro- and antifibrotic factors revealed changes in the production of MMPs and their inhibitors, growth factors, galectin-3, and pentraxin 3 in cells carrying mutation JAK2 in comparison with control non-modified cells.